Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07369011 · ClinicalTrials.gov registry record · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT07369011 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 800 participants, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT07369011, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study. Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eloralintide
Study Locations (20)
California
- Ark Clinical Research - Long Beach
- Collaborative Neuroscience Research, LLC - Los Alamitos
- Artemis Institute for Clinical Research - Riverside
Florida
- Flourish Research - Miami, LLC - Miami
- PharmaDev Clinical Research Institute, LLC - Miami
- Emerald Coast Neurology - Airport Boulevard - Pensacola
Georgia
- Teak Research Consults - Lawrenceville
- EBGS Clinical Research Center - Snellville
Alabama
- Cullman Clinical Trials - Cullman
Colorado
- Care Access - Aurora - Aurora
Louisiana
- Care Access - Shreveport 2 - Shreveport
Maryland
- Flourish Research - Bowie - Bowie
Michigan
- Revive Research Institute, Inc. - Southfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2028-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07369011
The ClinicalTrials.gov registry entry for NCT07369011 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 818-participant average among 1,053 other Obesity trials with a reported enrollment target. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07369011 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07369011 about?
NCT07369011 is a clinical study titled "A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight". The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who ...
What is the current status of trial NCT07369011?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2026-02-10. Estimated completion is 2028-04.
What conditions does trial NCT07369011 study?
This clinical trial studies the following conditions: Obesity, Overweight, Sleep Apnea, Obstructive.
What interventions are being tested in trial NCT07369011?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG).
Who is sponsoring clinical trial NCT07369011?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07369011 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.